Crossfund Sicav-Crossinvest Healthcare Fund A USD

Reference Data

ISIN LU1334634299
Valor Number 30671916
Bloomberg Global ID
Fund Name Crossfund Sicav-Crossinvest Healthcare Fund A USD
Fund Provider Crossinvest SA Lugano, Switzerland
Phone: +41 91 911 88 88
E-Mail: info@crossinvest.ch
Web: www.crossinvest.ch
Fund Provider Crossinvest SA
Representative in Switzerland FundPartner Solutions (Suisse) SA
Genève 75
Distributor(s) FundPartner Solutions (Suisse) SA
Genève 3
Asset Class Equities
EFC Category
Distribution Policy Accumulation
Home Country Luxembourg
Issuing Condition Combination of issuing commission charged by the fund management company and transaction fee charged by the fund
Redemption Condition Combination of redemption commission charged by the fund management company and transaction fee charged by the fund
Investment Strategy *** The investment objective of the Sub‐Fund is to achieve a long term capital appreciation by pursuing sector focus exposure opportunities in companies involved in health and personal care. These companies could participate in the research, clinical development or commercialization of medicines, equipment or services for disease treatment or life style improvement. The investment focus will be on industry leaders that offer premium growth and/or profitability prospects, pipeline and valuation upside. The Sub‐Fund is actively managed. The Sub‐Fund has no benchmark index and is not managed in reference to a benchmark index.
Peculiarities

Fund Prices

Current Price * 172.40 USD 08.01.2026
Previous Price * 173.51 USD 07.01.2026
52 Week High * 173.51 USD 07.01.2026
52 Week Low * 141.13 USD 07.08.2025
NAV * 172.40 USD 08.01.2026
Issue Price * 172.40 USD 08.01.2026
Redemption Price *
Closing Price *
Indicative Minimum Price
Fund Assets *** 54,793,175
Unit/Share Assets *** 12,194,324
Trading Information SIX

Performance

YTD Performance +2.36% 31.12.2025
08.01.2026
YTD Performance (in CHF) +3.09% 31.12.2025
08.01.2026
1 month +4.21% 08.12.2025
08.01.2026
3 months +9.40% 08.10.2025
08.01.2026
6 months +16.22% 08.07.2025
08.01.2026
1 year +12.46% 08.01.2025
08.01.2026
2 years +7.82% 08.01.2024
08.01.2026
3 years +12.89% 09.01.2023
08.01.2026
5 years +11.57% 08.01.2021
08.01.2026

Tax Data

Equity Participation Rate in %
Share of Total Fund Assets in %
Real Estate Rate in %
ADDI
ADDI Date

Top 10 Holdings ***

Eli Lilly and Co 7.57%
Novartis AG Registered Shares 4.59%
AbbVie Inc 4.46%
Novo Nordisk AS Class B 4.27%
UnitedHealth Group Inc 4.18%
Roche Holding AG 3.91%
Essilorluxottica 3.78%
AstraZeneca PLC 3.51%
Abbott Laboratories 3.28%
Merck & Co Inc 3.28%
Last data update 30.09.2025

Cost / Risk

TER *** 2.132%
TER date *** 31.08.2025
Performance Fee *** 15.00%
PTR
Max. Management Fee *** 1.50%
Ongoing Charges ***
SRRI ***
SRRI date *** 31.12.2025

Breakdowns

Equity Countries ***

Equity Sectors ***

Bond Sectors ***


* NAV / Issue Price exclusive commissions, for listed funds NAV or closing price
** Calculation of interim profit followed § 9 Satz 2 InvStG
*** Data source: Morningstar (Data is based on the rescaled long position of the holdings)